Brown Advisory
LGND icon

Brown Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

Brown Advisory’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,757
Closed -$554K – 1273
2023
Q4 		$554K Buy
+7,757
New +$458K ﹤0.01% 910
2019
Q2 		– Sell
-44,192
Closed -$3.46M – 1163
2019
Q1 		$3.46M Buy
44,192
+19,443
+79% +$1.47M 0.01% 516
2018
Q4 		$2.09M Buy
24,749
+10,962
+80% +$1.17M 0.01% 589
2018
Q3 		$2.36M Sell
13,787
-1,700
-11% -$256K 0.01% 606
2018
Q2 		$2M Buy
15,487
+2,766
+22% +$309K 0.01% 623
2018
Q1 		$1.31M Sell
12,721
-1,102
-8% -$109K ﹤0.01% 599
2017
Q4 		$1.18M Sell
13,823
-484
-3% -$42K ﹤0.01% 638
2017
Q3 		$1.22M Buy
14,307
+528
+4% +$41.8K ﹤0.01% 618
2017
Q2 		$1.04M Buy
13,779
+1,891
+16% +$132K ﹤0.01% 675
2017
Q1 		$785K Buy
11,888
+2,703
+29% +$178K ﹤0.01% 690
2016
Q4 		$582K Buy
9,185
+1,939
+27% +$122K ﹤0.01% 757
2016
Q3 		$461K Buy
7,246
+1,990
+38% +$146K ﹤0.01% 785
2016
Q2 		$391K Sell
5,256
-2,052
-28% -$152K ﹤0.01% 802
2016
Q1 		$488K Sell
7,308
-16
-0.2% -$972 ﹤0.01% 723
2015
Q4 		$495K Sell
7,324
-468
-6% -$28.9K ﹤0.01% 693
2015
Q3 		$417K Buy
7,792
+2,085
+37% +$127K ﹤0.01% 721
2015
Q2 		$359K Sell
5,707
-3,873
-40% -$211K ﹤0.01% 701
2015
Q1 		$461K Buy
9,580
+1,283
+15% +$49.2K ﹤0.01% 707
2014
Q4 		$276K Buy
8,297
+1,122
+16% +$36.5K ﹤0.01% 821
2014
Q3 		$211K Buy
7,175
+1,725
+32% +$57.3K ﹤0.01% 877
2014
Q2 		$212K Buy
5,450
+160
+3% +$6.49K ﹤0.01% 884
2014
Q1 		$222K Buy
+5,290
New +$221K ﹤0.01% 845

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown Advisory's LGND Position: Q1 2024 in Review

Brown Advisory sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 7,757 shares — an estimated $554K sold.

Brown Advisory first reported a position in LGND in Q1 2014 and held it in 22 quarters. The position peaked at $3.46M in Q1 2019. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Brown Advisory reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Brown Advisory sold 7,757 Ligand Pharmaceuticals shares in Q1 2024, an estimated $554K.
  • Brown Advisory first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 22 quarters.
  • Brown Advisory's Ligand Pharmaceuticals position peaked at $3.46M in Q1 2019.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Brown Advisory's 13F filing for Q1 2024, filed 24 Apr 2024.